582 related articles for article (PubMed ID: 26621126)
41. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
42. Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity.
Kim J; Watkins BA
J Nutr Biochem; 2014 Aug; 25(8):815-23. PubMed ID: 24854955
[TBL] [Abstract][Full Text] [Related]
43. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.
McIntosh BT; Hudson B; Yegorova S; Jollimore CA; Kelly ME
Br J Pharmacol; 2007 Dec; 152(7):1111-20. PubMed ID: 17922024
[TBL] [Abstract][Full Text] [Related]
44. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.
Béquet F; Uzabiaga F; Desbazeille M; Ludwiczak P; Maftouh M; Picard C; Scatton B; Le Fur G
Eur J Neurosci; 2007 Dec; 26(12):3458-64. PubMed ID: 18052990
[TBL] [Abstract][Full Text] [Related]
45. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I
Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698
[TBL] [Abstract][Full Text] [Related]
46. Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala.
Huang YC; Wang SJ; Chiou LC; Gean PW
J Neurosci; 2003 Nov; 23(32):10311-20. PubMed ID: 14614090
[TBL] [Abstract][Full Text] [Related]
47. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Kokona D; Thermos K
Exp Eye Res; 2015 Jul; 136():45-58. PubMed ID: 25989217
[TBL] [Abstract][Full Text] [Related]
48. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
49. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages.
Jiang LS; Pu J; Han ZH; Hu LH; He B
Cardiovasc Res; 2009 Mar; 81(4):805-13. PubMed ID: 19074161
[TBL] [Abstract][Full Text] [Related]
50. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle.
Baldassano S; Serio R; Mule' F
Eur J Pharmacol; 2008 Mar; 582(1-3):132-8. PubMed ID: 18234188
[TBL] [Abstract][Full Text] [Related]
51. A study of cannabinoid-1 receptors during the early phase of excitotoxic damage to rat spinal locomotor networks in vitro.
Veeraraghavan P; Dekanic A; Nistri A
Neuroscience; 2016 Oct; 333():214-28. PubMed ID: 27450568
[TBL] [Abstract][Full Text] [Related]
52. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
Khasabova IA; Yao X; Paz J; Lewandowski CT; Lindberg AE; Coicou L; Burlakova N; Simone DA; Seybold VS
Pharmacol Res; 2014 Dec; 90():67-75. PubMed ID: 25304184
[TBL] [Abstract][Full Text] [Related]
53. Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing.
Eroli F; Loonen ICM; van den Maagdenberg AMJM; Tolner EA; Nistri A
Neuropharmacology; 2018 Mar; 131():39-50. PubMed ID: 29225040
[TBL] [Abstract][Full Text] [Related]
54. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR; Stoneking SP; Ball JM; Tilghman BM; Washington CC; Hotaling KA; Johnson JO; Tobias JD
Naunyn Schmiedebergs Arch Pharmacol; 2007 Dec; 376(4):285-93. PubMed ID: 17960365
[TBL] [Abstract][Full Text] [Related]
55. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.
Citraro R; Russo E; Scicchitano F; van Rijn CM; Cosco D; Avagliano C; Russo R; D'Agostino G; Petrosino S; Guida F; Gatta L; van Luijtelaar G; Maione S; Di Marzo V; Calignano A; De Sarro G
Neuropharmacology; 2013 Jun; 69():115-26. PubMed ID: 23206503
[TBL] [Abstract][Full Text] [Related]
56. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons.
Llorente-Berzal A; Terzian AL; di Marzo V; Micale V; Viveros MP; Wotjak CT
Psychopharmacology (Berl); 2015 Aug; 232(15):2811-25. PubMed ID: 25814137
[TBL] [Abstract][Full Text] [Related]
57. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
58. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.
Al Kury LT; Voitychuk OI; Yang KH; Thayyullathil FT; Doroshenko P; Ramez AM; Shuba YM; Galadari S; Howarth FC; Oz M
Br J Pharmacol; 2014 Jul; 171(14):3485-98. PubMed ID: 24758718
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
60. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
Sarfaraz S; Afaq F; Adhami VM; Mukhtar H
Cancer Res; 2005 Mar; 65(5):1635-41. PubMed ID: 15753356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
